- Target disease: VL
- Main partners (since project start): BRAZIL: Rene Rachou Research Center– Fiocruz-MG, Belo Horizonte; Paediatric Hospital Joao Paulo II – FHEMIG, Belo Horizonte; Brasilia University; Montes Claros State University; Piaui Federal University, Teresina; Sergipe Federal University, Aracaju; Leishmaniasis Control Programme/Ministry of Health; Universidade Estadual do Rio de Janeiro; Hospital Sao José de Doencas Infecciosas, Fortaleza.
- Project start: February 2011
- Funding (since project start): CNPq/FINEP; Department for International Development (DFID), UK; Médecins Sans Frontières/Doctors without Borders, International; Medicor Foundation, Liechtenstein; Ministry of Health, Brazil; Spanish Agency for International Development Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland; Moreau Family, Brazil; Other private foundations and individuals.
In 2011, a Phase IV study sponsored by the Brazilian Ministry of Health was initiated at five sites in Brazil to evaluate the efficacy and safety of Amphotericin B deoxycholate, AmBisome® and a combination of AmBisome® and Glucantime®, in comparison to Glucantime®, the existing first-line treatment of VL. 378 patients were recruited. Brazil’s national guidelines for VL were revised in 2013 based on the interim safety data from the trial. While Glucantime® remains the first-line treatment, AmBisome® replaced Amphotericin B deoxycholate as a second-line treatment. The final results of this trial were presented to the Ministry of Health, and are expected to guide further policy change in Brazil.
Last update: February 2017